Company Snapshot
- Ticker
- BMY
- Name
- BMY
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 104364085230.000000
- Volume
- 7,651,347
- Avg Volume (3M)
- 14,477,199
BMY
BMY
Last update recent
51.21
+0.56
(+1.11%)
Market Cap
104364085230.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 48034000000.000000
- EPS
- 2.97
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 4.79%
- Net Income
- 6039000000.000000
- Net Margin
- 12.57%
- Payout Ratio
- 82.81%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 17.28
- Forward P/E
- None
- P/S
- 2.17
- P/B
- 5.61
- Beta
- None
- Debt / Equity
- 2.74
- Current Ratio
- 1.27
- Return on Equity
- 0.32%
- Return on Assets
- 0.06%
Technicals & Returns
- Distance vs 200 DMA
- 6.47%
- 200 DMA
- 48.10
- Distance vs 50 DMA
- 10.18%
- 50 DMA
- 46.48
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patien Read more
- Name
- BMY
- Industry
- Drug Manufacturers - General
- CEO
- Dr. Christopher S. Boerner Ph.D.
- Employees
- 34,100
- IPO Date
- 1972-06-01
- Phone
- 212 546 4000
- Address
- None
- Website
- https://www.bms.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-07-05 • $0.6
Latest News
Curated headlines from premium sources.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE: BMY), citing near-term catalysts.
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Frida…
Bristol Myers Squibb Company $BMY Shares Purchased by Cullen Capital Management LLC
Cullen Capital Management LLC lifted its position in Bristol Myers Squibb Company (NYSE: BMY) by 12.7% in the undefined quarter, according to the company in it…
2 Dividend Stocks to Double Up on Right Now
These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.